Loading...
Extensive clinical experience and recent reports from retrospective studies provide compelling evidence of both de novo and acquired resistance to abiraterone and enzalutamide in men with metastatic castration-resistant prostate cancer. Although both agents have significant activity in the disease, no data informs the clinician a priori of the potential utility of these agents for individual patients.
To predict response or resistance to enzalutamide or abiraterone in this setting, investigators prospectively evaluated whether presence of the androgen receptor (AR) splice variant 7 (AR-V7) in circulating tumor cells affects prostate-specific antigen (PSA) response, clinical or radiographic progression, and both progression-free and overall s…